Microbiome-Based Therapeutics – Thematic Intelligence

Reasons to buy the ‘Microbiome-Based Therapeutics’ thematic intelligence report:

• Examine the current utilization practices of microbiome-based therapies.
• Assess the barriers and opportunities associated with the use of microbiome-based therapies.
• Measure the expected use of microbiome-based therapies in the future.
• Identify major players in the microbiome industry.
• Analyze market trends and deal-making activities in the microbiome sector.
• Get an overview of marketed and pipeline products.

How is our ‘Microbiome-Based Therapeutics’ report unique from other reports in the market?

• Develop business strategies by understanding the trends shaping and driving the global microbiome-targeting therapy market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global microbiome-targeting therapy market in the future.
• Design your development strategy through a review of potential novel targets or combinations across indications.
• Understand the challenges and strategies impacting the development of microbiome-targeting therapy agents in preclinical studies and clinical trials.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the classes of microbiome-targeting therapy and indications that present maximum opportunities for consolidations, investments, and strategic partnerships.

We recommend this valuable source of information to anyone involved in:

• ​Pharmaceutical Industries (Big Pharma, Small Biotech, Start-ups, etc.)
• Clinical Research Organisations (CROs)
• Pharma Manufacturers (Innovative, Biotech, Generics, Biosimilars, Rare/Orphan Disease)/Distributors
• Healthcare Organisations (Payers, HTA Bodies, Reimbursement Groups, Government Healthcare Organizations)
• Consulting and Professional Services (e.g., Investment Companies, Investment Banks, Equity Companies, etc.)
• Pharmaceutical Industry Suppliers (e.g., Consulting Companies, CMOs, CDMOs, CROs, Technology Vendors)
• Financial Institutions (Investors in Pharma/Biotech, Pricing Consultancies)/Parallel Trade Organisations

To Get a Snapshot of the Microbiome-Based Therapeutics Thematic Report

Download a Free Report Sample

Microbiome-Based Therapeutics Market Report Overview

The microbiome, encompassing a vast array of microorganisms inhabiting the human body, has garnered significant attention for its role in health and disease. Recent advancements in microbiome research along with recent approvals of microbiome-based therapies, such as Ferring Therapeutics’ Rebyota and Seres Therapeutics’ Vowst, are expected to further accelerate the integration of microbiome treatments into clinical settings. By harnessing knowledge derived from the expanding research, the microbiome has the potential to offer new avenues for personalized medicine and targeted interventions. However, while awareness of the microbiome seems to be growing and acceptance of its potential benefits is increasing, adoption remains varied.

In the “Microbiome-Based Therapeutics – Thematic Intelligence” report, GlobalData assesses the current landscape of microbiome-based therapeutics in the seven major markets. The major markets include the US, France, Germany, Italy, Spain, the UK, and Japan. The report also examines healthcare professionals’ opinions and utilization of these therapies.

Microbiome – Value Chain

The key value chain components of the Microbiome are oral LBP, vaginal LBP, topical LBP, and intravenous LBP among others. Oral LBP includes GI indications, respiratory indications, CNS, immunology, and ophthalmology among others.

Microbiome Value Chain
Buy the Full Report for More Insights into the Microbiome Value Chain

Download a Free Sample Report

Trends Impacting Microbiome Research

The key trends impacting Microbiome research are the potential for novel therapies, personalized medicine, and antibiotic resistance among others. For instance, growing interest in the development of microbiome-targeting therapies has led to a steadily expanding pipeline over the last decade. Although most of these candidates are still in the earlier stages of development, promising advancements hold significant potential for novel therapies. Globally, there are currently more than 410 planned, completed, or ongoing clinical trials related to microbiome therapies.

Microbiome-Based Therapeutics – Pipeline and Marketed Products as per Therapy area

The infectious diseases area holds the most focus for the microbiome pipeline products. It also has the most microbiome therapies approved. This is followed by gastrointestinal disorders and oncology. One of the underlying factors contributing to the high interest rate in infectious diseases is the established process of FMT for the treatment of C. difficile, as well as very recent approvals of C. difficile therapies.

Buy the Full Report for More Insights into the Pipeline and Marketed Products of Microbiome-Based Therapeutics

Download a Free Sample Report

Microbiome-Based Therapeutics – Competitive Landscape

The key companies playing an active role in microbiome development are Microgen, Osel, IQVIA, Lonza, and ICON among others.

Company filings provide important insights into companies’ strategic focus, investment priorities, and research direction. The mentions of microbiome-based therapies in companies’ annual fillings have been steadily increasing since 2017, peaking at more than 90 in 2022. This may suggest that the microbiome is becoming a more significant area of interest.

Key Microbiome-Based Therapeutics Companies
Buy the Full Report for More Company Insights into Microbiome-Based Therapeutics

Download a Free Sample Report